RESUMO
Purpose: Vitiligo is an idiopathic depigmenting skin disorder. The study compares the efficacy of topical tacrolimus 0.1% with calcipotriol/betamethasone dipropionate in vitiligo patients receiving NB-UVB treatment.Materials and methods: Forty-one adult patients with generalized type vitiligo were recruited. Patients were assigned to phototherapy and then classified into either group one (20 patients), receiving calcipotriol/betamethasone dipropionate cream (D group), or group two (21 patients), receiving tacrolimus 0.1% ointment (T group). They were followed-up at 3 and 6 months.Results: The D group witnessed an increase in the repigmentation area from 35.4% in the third month to 54.7% in the sixth month (p = 0.001) and the T group from 32.2% to 45.6% (p = 0.011). However, the differences between the treatment groups were not statistically significant. Body sites demonstrated different levels of improvement ranging from the highest in the face to the lowest in the Hand & Feet with the other body sites in between. A negative correlation was identified between the duration since diagnosis and the response to D treatment (3 months: r = -0.612, p = 0.007; 6 months: r = -0.755, p = 0.001).Conclusions: Although both combinations are efficacious, they did not significantly differ in efficacy at three and six months follow-up points.Clinical trial registration: The study was registered at clinicaltrials.gov (NCT04440371).
Assuntos
Hipopigmentação , Vitiligo , Adulto , Humanos , Betametasona/uso terapêutico , Pomadas , Tacrolimo/uso terapêutico , Vitiligo/tratamento farmacológicoRESUMO
This article summarizes a presentation titled 'The role of topical therapies along the psoriasis patient journey' held at the Satellite Symposium of the 30th European Academy of Dermatology and Venereology Congress. During this session, the role of topical treatments in the management of psoriasis was presented, with a particular focus on the current unmet needs and data gaps. Psoriasis plays a significant role in a patient's daily life, impacting them not only physically but also psychologically and socially. The disease burden increases with duration and severity. Topical therapies are the keystone of the management of psoriasis. About 70%-80% of patients present a mild-to-moderate form of psoriasis that can be successfully treated with topical agents. According to a German recommendation, patients with mild psoriasis should initiate a topical therapy in combination with skin care products. In the real-life setting, the calcipotriol/betamethasone dipropionate (CAL/BDP) fixed combination was the most prescribed topical treatment for beyond-mild patients in Germany, Spain and the United Kingdom. Healthcare professionals also often or very often prescribed topicals as an alternative to non-biologic systemics in certain situations, such as patient preference (51%), contraindication (50%) and to limit side effects (26%). Adjunctive topical therapy to patients using systemic therapy is used to optimize treatment outcomes and improving the quality of life for patients. Topical treatments can be also effective in severe forms of psoriasis. However, there are still some gaps and unmet needs on topical therapy. Ineffectiveness, patient dissatisfaction and adherence are the largest barriers to treatment success. Main strengths of topical treatments include the availability of various topical ingredients and galenics, the adaptability to different anatomical areas and the possible combination with phototherapy and systemics. Moreover, patients in specific situations can benefit from switching to topical treatments (e.g. pregnancy or surgery).
Assuntos
Fármacos Dermatológicos , Psoríase , Humanos , Qualidade de Vida , Motivação , Fármacos Dermatológicos/uso terapêutico , Psoríase/tratamento farmacológico , Betametasona/uso terapêutico , Administração Tópica , Resultado do Tratamento , Combinação de MedicamentosRESUMO
Aberrant levels of reactive oxygen species (ROS) are potential mechanisms that contribute to both cancer therapy efficacy and the side effects of cancer treatment. Upregulation of the non-canonical redox-sensitive NF-kB family member, RelB, confers radioresistance in prostate cancer (PCa). We screened FDA-approved compounds and identified betamethasone (BET) as a drug that increases hydrogen peroxide levels in vitro and protects non-PCa tissues/cells while also enhancing radiation killing of PCa tissues/cells, both in vitro and in vivo. Significantly, BET increases ROS levels and exerts different effects on RelB expression in normal cells and PCa cells. BET induces protein expression of RelB and RelB target genes, including the primary antioxidant enzyme, manganese superoxide dismutase (MnSOD), in normal cells, while it suppresses protein expression of RelB and MnSOD in LNCaP cells and PC3 cells. RNA sequencing analysis identifies B-cell linker protein (BLNK) as a novel RelB complementary partner that BET differentially regulates in normal cells and PCa cells. RelB and BLNK are upregulated and correlate with the aggressiveness of PCa in human samples. The RelB-BLNK axis translocates to the nuclear compartment to activate MnSOD protein expression. BET promotes the RelB-BLNK axis in normal cells but suppresses the RelB-BLNK axis in PCa cells. Targeted disruptions of RelB-BLNK expressions mitigate the radioprotective effect of BET on normal cells and the radiosensitizing effect of BET on PCa cells. Our study identified a novel RelB complementary partner and reveals a complex redox-mediated mechanism showing that the RelB-BLNK axis, at least in part, triggers differential responses to the redox-active agent BET by stimulating adaptive responses in normal cells but pushing PCa cells into oxidative stress overload.
Assuntos
Neoplasias da Próstata , Fator de Transcrição RelB , Proteínas Adaptadoras de Transdução de Sinal/metabolismo , Betametasona/farmacologia , Betametasona/uso terapêutico , Humanos , Masculino , Oxirredução , Neoplasias da Próstata/tratamento farmacológico , Neoplasias da Próstata/genética , Neoplasias da Próstata/radioterapia , Tolerância a Radiação , Espécies Reativas de Oxigênio/metabolismo , Fator de Transcrição RelB/genética , Fator de Transcrição RelB/metabolismoRESUMO
BACKGROUND This retrospective study aimed to investigate outcomes and hospitalization rates in patients with a confirmed diagnosis of early COVID-19 treated at home with prescribed and non-prescribed treatments. MATERIAL AND METHODS The medical records of a cohort of 158 Italian patients with early COVID-19 treated at home were analyzed. Treatments consisted of indomethacin, low-dose aspirin, omeprazole, and a flavonoid-based food supplement, plus azithromycin, low-molecular-weight heparin, and betamethasone as needed. The association of treatment timeliness and of clinical variables with the duration of symptoms and with the risk of hospitalization was evaluated by logistic regression. RESULTS Patients were divided into 2 groups: group 1 (n=85) was treated at the earliest possible time (<72 h from onset of symptoms), and group 2 (n=73) was treated >72 h after the onset of symptoms. Clinical severity at the beginning of treatment was similar in the 2 groups. In group 1, symptom duration was shorter than in group 2 (median 6.0 days vs 13.0 days, P<0.001) and no hospitalizations occurred, compared with 19.18% hospitalizations in group 2. One patient in group 1 developed chest X-ray alterations and 2 patients experienced an increase in D-dimer levels, compared with 30 and 22 patients, respectively, in group 2. The main factor determining the duration of symptoms and the risk of hospitalization was the delay in starting therapy (P<0.001). CONCLUSIONS This real-world study of patients in the community showed that early diagnosis and early supportive patient management reduced the severity of COVID-19 and reduced the rate of hospitalization.
Assuntos
Tratamento Farmacológico da COVID-19 , COVID-19/diagnóstico , Hospitalização/estatística & dados numéricos , Tempo para o Tratamento/estatística & dados numéricos , Idoso , Idoso de 80 Anos ou mais , Aspirina/uso terapêutico , Betametasona/uso terapêutico , Estudos de Coortes , Suplementos Nutricionais , Diagnóstico Precoce , Feminino , Flavonoides/uso terapêutico , Seguimentos , Heparina de Baixo Peso Molecular/uso terapêutico , Humanos , Indometacina/uso terapêutico , Itália , Masculino , Pessoa de Meia-Idade , Omeprazol/uso terapêutico , Gravidade do Paciente , Estudos Retrospectivos , Medição de Risco , SARS-CoV-2 , Tempo , Resultado do TratamentoRESUMO
OBJECTIVE: Combination topical clotrimazole/ betamethasone dipropionate (C-BM) contains a high-potency topical corticosteroid and is not infrequently prescribed for inappropriate patient groups and body sites. Use of C-BM can lead to inadequate clearance or exacerbation of fungal infections as well as cutaneous atrophy, striae, and other skin maladies. METHODS: We performed a retrospective chart review of 1,978 clinical visits where C-BM was prescribed within the University of Utah Health system between 2014 and 2018 to better understand current prescribing patterns. RESULTS: 1,974 prescriptions were written for C-BM. 91.6% of patients were at least the recommended age of 17 years. C-BM was most commonly prescribed for rashes of an inflammatory (42.2%) or fungal nature (38.1%). Clotrimazole/betamethasone dipropionate was prescribed for sensitive areas (face, axillae, groin or diaper region) in 48.9% of patients. Family medicine clinicians prescribed 58.3% of C-BM prescriptions, whereas dermatology clinicians accounted for 3.4%. CONCLUSION: We strongly recommend clinicians use alternative treatments for rashes or refer to dermatologists.
Assuntos
Antifúngicos/uso terapêutico , Betametasona/análogos & derivados , Clotrimazol/uso terapêutico , Glucocorticoides/uso terapêutico , Micoses/tratamento farmacológico , Uso Excessivo de Medicamentos Prescritos/estatística & dados numéricos , Adolescente , Adulto , Betametasona/uso terapêutico , Criança , Combinação de Medicamentos , Feminino , Humanos , Modelos Logísticos , Masculino , Estudos RetrospectivosRESUMO
BACKGROUND: Follicular unit extraction (FUE) grafting is a surgical procedure which provides the vitiliginous patches with undifferentiated stem cells of the hair follicles. It has been postulated that adjuvant therapy enhances the results. This is the first study to assess two different adjuvant therapies vs FUE alone. AIMS: To study the efficiency of FUE alone or combined with either topical calcipotriol betamethasone dipropionate (CBD) or NB-UVB phototherapy in cases of nonsegmental stable vitiligo. To assess the role of dermoscopy in monitoring the pattern and degree of repigmentation. PATIENTS/ METHODS: 53 patients with 94 lesions with stable nonsegmental vitiligo were divided into three groups. Group 1 (n = 16) with 30 lesions received FUE alone. Group 2 (n = 18) with 32 lesions received FUE plus topical CBD. Group 3 (n = 19) with 32 lesions received FUE plus NB-UVB phototherapy. Assessment was done by grades of repigmentation, color match, percent of size reduction, and immunohistochemical evaluation of perilesional CD8+T lymphocytes. RESULTS: The fastest onset of repigmentation was observed in both groups 2 and 3 in the second week (16.7%, 10.5%, respectively).Group 2 achieved the best response by all methods of assessment. Perifollicular diffuse repigmentation was the commonest dermoscopic pattern in 60 lesions (63.8%). There was a statistically significant decrease in perilesional CD8+T lymphocytes after 4 months. CONCLUSION: FUE is an effective method of surgical treatment of stable vitiligo, and topical CBD as a new adjuvant therapy is successful in targeting the immunological background of vitiligo. Dermoscopy has an essential role in monitoring the repigmentation response.
Assuntos
Terapia Ultravioleta , Vitiligo , Betametasona/análogos & derivados , Betametasona/uso terapêutico , Calcitriol/análogos & derivados , Calcitriol/uso terapêutico , Terapia Combinada , Humanos , Resultado do Tratamento , Vitiligo/tratamento farmacológicoAssuntos
Celulite/tratamento farmacológico , Etilenodiaminas/efeitos adversos , Mesoterapia/efeitos adversos , Mesoterapia/métodos , Urticária/induzido quimicamente , Tecido Adiposo/patologia , Betametasona/uso terapêutico , Fármacos Dermatológicos/uso terapêutico , Feminino , Glucocorticoides/uso terapêutico , Humanos , Pessoa de Meia-Idade , Prurido/induzido quimicamente , Prurido/tratamento farmacológico , Urticária/tratamento farmacológicoRESUMO
Preterm birth accounts for only 11% of live births but contributes to up to 75% of neonatal mortality and more than half of long-term morbidity. Targeted interventions to reduce the most common causes of perinatal morbidity and mortality include intrapartum group B Streptococcus prophylaxis, magnesium sulfate for fetal neuroprotection, antenatal corticosteroids for fetal lung maturity, latency antibiotics for preterm premature rupture of membranes, and tocolysis to allow corticosteroid administration and transfer to a tertiary care center. This article reviews the evidence for interventions to improve outcomes for fetuses at risk for preterm delivery at different gestational ages.
Assuntos
Antibacterianos/uso terapêutico , Anticonvulsivantes/uso terapêutico , Glucocorticoides/uso terapêutico , Sulfato de Magnésio/uso terapêutico , Nascimento Prematuro/terapia , Tocolíticos/uso terapêutico , Betametasona/uso terapêutico , Dexametasona/uso terapêutico , Feminino , Ruptura Prematura de Membranas Fetais/terapia , Maturidade dos Órgãos Fetais , Viabilidade Fetal , Humanos , Indometacina/uso terapêutico , Sepse Neonatal/prevenção & controle , Fármacos Neuroprotetores/uso terapêutico , Nifedipino/uso terapêutico , Gravidez , Infecções Estreptocócicas/prevenção & controle , Streptococcus agalactiae , TocóliseRESUMO
Skin models mimicking features of psoriasis-related inflammation are needed to support the development of new drugs in dermatology. Reconstructed skin models lack tissue complexity, including a fully competent skin barrier, and presence and/or diversity of immune cells. Here, we describe InflammaSkin®, a novel human Th17-driven ex vivo skin inflammation model. In this model, skin-resident T cells are in situ activated by intradermal injection of anti-CD3 and anti-CD28 antibodies and Th17 cell polarization is sustained by culture in a chemically defined medium supplemented with IL-1ß, IL-23 and TGF-ß for seven days. The acquired Th17 signature is demonstrated by the sustained secretion of IL-17A, IL-17AF, IL-17F, IL-22, IFN-γ, and to some degree IL-15 and TNF-α observed in the activated ex vivo skin inflammation model compared with the non-activated skin model control. Furthermore, expression of S100A7 and Keratin-16 by keratinocytes and loss of epidermal structure integrity occur subsequently to in situ Th17cell activation, demonstrating cellular crosstalk between Th17 cells and keratinocytes. Finally, we demonstrate the use of this model to investigate the modulation of the IL-23/IL-17 immune axis by topically applied anti-inflammatory compounds. Taken together, we show that by in situ activation of skin-resident Th17 cells, the InflammaSkin® model reproduces aspects of inflammatory responses observed in psoriatic lesions and could be used as a translational tool to assess efficacy of test compounds.
Assuntos
Dermatite/imunologia , Ativação Linfocitária , Modelos Biológicos , Células Th17/imunologia , Anti-Inflamatórios/uso terapêutico , Anticorpos , Betametasona/análogos & derivados , Betametasona/uso terapêutico , Antígenos CD28/imunologia , Complexo CD3/imunologia , Comunicação Celular , Meios de Cultura , Dermatite/tratamento farmacológico , Humanos , Interferon gama/metabolismo , Interleucina-15/metabolismo , Interleucina-17/metabolismo , Interleucinas/metabolismo , Queratina-16/metabolismo , Queratinócitos/metabolismo , Inibidores da Fosfodiesterase 4/uso terapêutico , Proteína A7 Ligante de Cálcio S100/metabolismo , Células Th17/metabolismo , Fator de Necrose Tumoral alfa/metabolismo , Interleucina 22RESUMO
BACKGROUND: Meralgia paresthetica (MP) is an entrapment mononeuropathy of the lateral femoral cutaneous nerve (LFCN), in which conservative treatment options are not always sufficient. OBJECTIVES: The aim of this study was to evaluate the efficacy of ultrasound (US)-guided LFCN injection in the management of MP by comparing with transcutaneous electrical nerve stimulation (TENS) therapy and sham TENS therapy. STUDY DESIGN: A prospective, randomized, sham-controlled study. SETTING: Health Sciences University Training and Research Hospital in Turkey. METHODS: Patients diagnosed with LFCN compression with clinical and electrophysiological findings were included in this study. Patients were randomly assigned to 3 groups: (1) US-guided injection group, (2) TENS group, and (3) sham TENS group. The blockage of the LFCN was performed for therapeutic MP management in group 1. Ten sessions of conventional TENS were administered to each patient 5 days per week for 2 weeks, for 20 minutes per daily session in group 2, and sham TENS was applied to group 3 with the same protocol. Visual Analog Scale (VAS), painDETECT questionnaire, Semmes-Weinstein monofilament test (SWMt), Pittsburgh Sleep Quality Index (PSQI), and health-related quality of life (36-Item Short Form Health Survey [SF-36]) at onset (T1), 15 days after treatment (T2), and 1 month after treatment (T3) were used for evaluation. Patients and the investigator who evaluated the results were blinded to the treatment protocol during the study period. RESULTS: A total of 54 of the 62 patients (group 1 n = 17, group 2 n = 16, group 3 n = 21) completed the study, 3 patients from group 1, 4 patients from group 2, and 1 patient from group 3 dropped out during the follow-up period. The mean changes in painDETECT and SWMt scores showed a statistically significant difference between groups in favor of group 1 at T2 and T3 compared with T1 (P < 0.05). There was no statistically significant difference between groups in terms of VAS, SF-36, and PSQI scores (P > 0.05). In-group analysis of VAS scores showed a statistically significant decrease in T2 and T3 compared with T1 in group 1 (P < 0.05). In-group analysis of the VAS scores statistically significant decrease was shown in T2 compared with T1 in group 2 (P < 0.05). In-group analysis of painDETECT scores statistically significant decrease was shown in T2 and T3 compared with T1 in all groups (P < 0.05). In-group analysis of SWMt scores statistically significant decrease was shown in T2 and T3 compared with T1 in group 1 (P < 0.05). In-group analysis of SF-36 and PSQI scores, there was no statistically significant decrease in all groups (P > 0.05). LIMITATIONS: The limitation of the study was a short follow-up period. CONCLUSIONS: US-guided LFCN injection and TENS may be therapeutic options for MP treatment, however, for patients with neuropathic pain symptoms, US-guided LFCN injection may be a safe and alternative method to conservative treatment. KEY WORDS: Meralgia paresthetica, ultrasound-guided injection, transcutaneous electrical nerve stimulation.
Assuntos
Anestésicos Locais/uso terapêutico , Neuropatia Femoral/terapia , Glucocorticoides/uso terapêutico , Bloqueio Nervoso/métodos , Adulto , Betametasona/análogos & derivados , Betametasona/uso terapêutico , Tratamento Conservador/métodos , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Prilocaína/uso terapêutico , Estudos Prospectivos , Qualidade de Vida , Estimulação Elétrica Nervosa Transcutânea/métodos , Resultado do Tratamento , Turquia , Ultrassonografia de IntervençãoRESUMO
Keloid scars result from excess collagen deposition in the dermis or subcutaneous tissue in response to surgery or tissue trauma. The penis is a rare site for keloid formation, even in predisposed individuals. Only few cases of penile keloids have been reported so far. In this report, we present penile keloids complicating neonatal circumcision in twin brothers. Risk of recurrence in previous reports and measures to guard against its occurrence are also discussed.
Assuntos
Anti-Inflamatórios/uso terapêutico , Betametasona/uso terapêutico , Queloide/prevenção & controle , Massagem , Prevenção Secundária/métodos , Pré-Escolar , Circuncisão Masculina/efeitos adversos , Humanos , Queloide/etiologia , Queloide/cirurgia , Masculino , Pênis , Complicações Pós-Operatórias/etiologia , Complicações Pós-Operatórias/prevenção & controle , RecidivaRESUMO
Purpose Long-term outcomes of sudden sensorineural hearing loss (SSNHL) are poorly studied. The recurrence rate is heterogeneous, and the prognosis of relapses is uncertain. The aim of this retrospective study was to evaluate the recurrence rate of SSNHL and to analyze the correlation with clinical and audiometric characteristics. Method Seventy-three patients with idiopatic SSNHL were evaluated. Clinical and audiometric features were recorded. Seventy patients (95.8%) had at least a 2-year follow-up, whereas 50 (68.4%) had a 5-year follow-up. Results Two- and 5-year recurrence rates were 5.60% and 10.34%, respectively. Mean time lapse between 1st episode and recurrence was 29.33 ± 26.60 months. About 70% of patients had a partial recovery at recurrence. The same ear was affected in 42.8% of patients, the contralateral ear was affected in 42.8% of patients, and recurrence was bilateral in 14.4% of cases. Recurrence correlated only with the presence of tinnitus during follow-up. However, the small number of participants with recurrence represented a limiting factor of our study. Conclusions Recurrences of SSNHL are rare events that can involve ipsilateral or contralateral ear. Further studies are necessary to identify predictors of recurrence.
Assuntos
Diuréticos Osmóticos/uso terapêutico , Glucocorticoides/uso terapêutico , Perda Auditiva Neurossensorial/terapia , Perda Auditiva Súbita/terapia , Oxigenoterapia Hiperbárica , Recuperação de Função Fisiológica , Administração Intravenosa , Administração Oral , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Audiometria de Tons Puros , Betametasona/uso terapêutico , Criança , Feminino , Perda Auditiva Neurossensorial/fisiopatologia , Perda Auditiva Súbita/fisiopatologia , Humanos , Injeção Intratimpânica , Estudos Longitudinais , Masculino , Manitol/uso terapêutico , Pessoa de Meia-Idade , Recidiva , Retratamento , Fatores de Tempo , Adulto JovemRESUMO
The goal of this study was to elucidate the anti-pruritic and anti-inflammatory efficacy of ruxolitinib cream in experimentally-induced dermatitis. Atopic dermatitis (AD), the most common chronic relapsing inflammatory skin disease, significantly impairs patients' quality of life, with pruritus being a common complaint. The sensation of itch results from the interplay between epidermal barrier dysfunction, upregulated immune signaling and the activation of the central nervous system. The Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway plays a central role in pro-inflammatory cytokine signaling in AD. Ruxolitinib cream is a potent and selective JAK1/2 inhibitor currently undergoing clinical evaluation in adults with mild-to-moderate AD (NCT03745638, NCT03920852 and NCT03745651). The efficacy of ruxolitinib cream was tested in murine models of acute and chronic dermatitis and was also characterized in an ex vivo human skin dermatitis model. Ruxolitinib cream was highly effective at ameliorating disease symptoms in multiple murine dermatitis models through downregulation of T helper (Th)2-driven inflammation, resulting in reduced skin thickening and decreased itch. Pathway analysis of mouse ear tissue and human skin explants underscored the role for ruxolitinib in ameliorating inflammation and reducing itch via modulation of the JAK-STAT pathway. Together, the data offer a strong rationale for the use of ruxolitinib cream as a potent therapeutic agent for the clinical management of atopic dermatitis.
Assuntos
Dermatite/tratamento farmacológico , Inibidores de Janus Quinases/uso terapêutico , Prurido/tratamento farmacológico , Pirazóis/uso terapêutico , Administração Cutânea , Animais , Betametasona/administração & dosagem , Betametasona/uso terapêutico , Clobetasol/administração & dosagem , Clobetasol/uso terapêutico , Citocinas/biossíntese , Citocinas/genética , Citocinas/toxicidade , Modelos Animais de Doenças , Toxidermias/tratamento farmacológico , Toxidermias/imunologia , Avaliação Pré-Clínica de Medicamentos , Feminino , Fluoresceína-5-Isotiocianato/toxicidade , Asseio Animal/efeitos dos fármacos , Humanos , Técnicas In Vitro , Interleucina-33/genética , Inibidores de Janus Quinases/administração & dosagem , Subpopulações de Linfócitos/efeitos dos fármacos , Subpopulações de Linfócitos/imunologia , Camundongos , Camundongos Endogâmicos BALB C , Camundongos Transgênicos , Nitrilas , Pomadas , Técnicas de Cultura de Órgãos , Pirazóis/administração & dosagem , Pirimidinas , Distribuição Aleatória , Transdução de Sinais/efeitos dos fármacos , Pele/efeitos dos fármacos , Organismos Livres de Patógenos Específicos , Linfócitos T Auxiliares-Indutores/efeitos dos fármacos , Linfócitos T Auxiliares-Indutores/imunologia , Transcriptoma , Linfopoietina do Estroma do TimoRESUMO
To evaluate and compare the therapeutic effects of corticosteroid and ozone injections in the alleviation of pain associated with chronic lateral epicondylitis . Data was collected from the medical records of 80 patients (56 women, 24 men ; average age : 45.8±7.5). Corticosteroid injection was performed once a week for three times, and ozone was injected 6-8 times at 3 day intervals. No additional analgesics were given. Pain assessment was made by means of Verhaar scores before and after the first injection, on 3rd, 6th and 9th months. The duration of pain was 24.4±12.5 months and the right side was more commonly affected (47, 58.8% vs. 33, 41.2%). Corticosteroid and ozone groups were similar with respect to age (p=0.45), gender distribution (p=0.43) and side of epicondylitis (p=0.88). Pain scores at rest, at compression and on activity were not different in two groups before and following injection. Notably, ozone group displayed better scores compared to corticosteroid in terms of pain on 3rd, 6th and 9th months after injection (p<0.001 for all). Our results demonstrated that ozone injection can be an effective therapeutic option for CLE patients who are refractory to conservative treatment.
Assuntos
Corticosteroides/uso terapêutico , Betametasona/análogos & derivados , Dor Crônica/tratamento farmacológico , Ozônio/uso terapêutico , Manejo da Dor/métodos , Cotovelo de Tenista/complicações , Corticosteroides/administração & dosagem , Betametasona/administração & dosagem , Betametasona/uso terapêutico , Doença Crônica , Esquema de Medicação , Feminino , Humanos , Injeções Intra-Articulares , Masculino , Pessoa de Meia-Idade , Ozônio/administração & dosagem , Medição da Dor , Estudos RetrospectivosRESUMO
OBJECTIVES: The aim of this study was to investigate the effect of a piriformis injection on neuropathic pain in patients with piriformis syndrome. METHODS: Thirty patients with unilateral hip and/or leg pain, a positive FAIR test (increased H-reflex latency with Flexion, Adduction and Internal Rotation), and a trigger point at the piriformis muscle were enrolled in this prospective study. All of the patients exhibited neuropathic pain scored according to the Douleur Neuropathique 4 (DN4) of ≥4 for at least 6 months. All of the patients received 4 mL of lidocaine 2%+1 mL of betamethazone to the piriformis muscle under the guidance of ultrasound. The Numeric Rating Scale (NRS), DN4, and the painDETECT (PD) questionnaire were used for outcome assessment. RESULTS: A statistically significant improvement was seen in all scores (p<0.001) when both first week and first month results were compared with the baseline values. Comparison of the first week results with those of the first month revealed a statistically significant improvement in only the NRS and PD scores (p<0.001). The greatest improvement in all scores was seen in the first week after the injection. A mild increase was seen in all scores at the first month compared to the first week. CONCLUSION: A piriformis injection was found to be effective for both somatic and neuropathic pain in piriformis syndrome patients. Long-term follow-up is needed in order to consider this option alongside other treatment alternatives, like botulinum toxin and myofascial release.
Assuntos
Anestésicos Locais/uso terapêutico , Anti-Inflamatórios/uso terapêutico , Betametasona/uso terapêutico , Lidocaína/uso terapêutico , Neuralgia/tratamento farmacológico , Síndrome do Músculo Piriforme/tratamento farmacológico , Anestésicos Locais/administração & dosagem , Anti-Inflamatórios/administração & dosagem , Betametasona/administração & dosagem , Combinação de Medicamentos , Feminino , Humanos , Injeções Intramusculares , Lidocaína/administração & dosagem , Masculino , Pessoa de Meia-Idade , Neuralgia/fisiopatologia , Medição da Dor , Síndrome do Músculo Piriforme/fisiopatologia , Estudos Prospectivos , Resultado do TratamentoRESUMO
Introduction: The goal of our prospective study was to assess the efficacy of the topical Platelet-rich plasma on reducing superficial perioral wrinkles and restoring the dermal matrix. Materials and methods: 50 women with moderate to severe perioral wrinkles were treated on the perioral area by a single session of fractional CO2 laser skin resurfacing plus intradermal injection of prp. 25 patients (group 1) applied topically prp twice a day for 12 weeks as post laser treatment. 25 (group 2) applied gentamicin and betamethasone twice a day for the first 7 days and then hyaluronic acid gel for the following 12 weeks. Results: In group 1, moisture (p < 0.001), amount of collagen fiber (p < 0.001) skin elasticity (p < 0.001), PSAl (p < 0.001) and SSAl (p < 0.001) improved significantly. In group 2 all the parameters investigated improved but did not reach significant difference. Discussion: Our medical device with a plasma-like formulation is able to maintain prp active for a period of 7 days so patients are able to apply topically growth factors at home. Conclusions: Our prospective study proves that the use of topical prp reduces superficial perioral wrinkles and restore dermal matrix when used at home for 12 weeks.
Assuntos
Plasma Rico em Plaquetas , Medicina Regenerativa/métodos , Envelhecimento da Pele , Administração Cutânea , Adulto , Antibacterianos/uso terapêutico , Anti-Inflamatórios/uso terapêutico , Betametasona/uso terapêutico , Colágeno/metabolismo , Terapia Combinada , Técnicas Cosméticas , Face , Feminino , Gentamicinas/uso terapêutico , Humanos , Ácido Hialurônico/uso terapêutico , Lasers de Gás , Terapia com Luz de Baixa Intensidade/efeitos adversos , Terapia com Luz de Baixa Intensidade/métodos , Masculino , Pessoa de Meia-Idade , Satisfação do Paciente , Estudos Prospectivos , RejuvenescimentoRESUMO
OBJECTIVE: The aim of this randomized controlled trial was to evaluate the safety and efficacy of neodymium: yttrium aluminum garnet laser treatment of lichen sclerosus (LS) by comparing it with topical corticosteroid treatment. METHODS: A total of 40 female patients with vulvar LS were randomized 1:1 into a study (laser) group and a control (topical corticosteroids) group. The laser group received three laser treatments. Blinded evaluators evaluated biopsies and graded improvement on clinical photographs at baseline and at 3 months. Patients graded the intensity of symptoms on a 0 to 10 visual analogue scale at baseline and 1-, 3-, and 6-month follow-up. Patients also rated the tolerability of laser treatments, and side effects were monitored. (Canadian Task Force classification I) RESULTS: Laser treatment discomfort was on average 1.5 of 10 on the visual analogue scale. At 1- and 3-month follow-up, patients in the laser group had significantly greater improvement in LS symptoms (burning, itching, pain, and dyspareunia), better patient satisfaction, and greater reduction of sclerosis than patients in the topical corticosteroid group. At 6-month follow-up, the improvement of symptoms in the laser group was still significant. The correct order of photographs (before and after treatment) was assigned significantly more often in the laser-treated patients compared with the control group. CONCLUSION: Laser therapy for LS caused minimal patient discomfort during the treatment, with no adverse effects, and demonstrated better efficacy than in the control group, with significant improvement lasting up to 6 months. Laser therapy is a promising option for patients not responding to topical corticosteroid therapy or patients wishing to reduce long-term corticosteroid maintenance use.
Assuntos
Lasers de Estado Sólido/uso terapêutico , Líquen Escleroso e Atrófico/radioterapia , Terapia com Luz de Baixa Intensidade/estatística & dados numéricos , Adulto , Idoso , Betametasona/uso terapêutico , Feminino , Glucocorticoides/uso terapêutico , Humanos , Líquen Escleroso e Atrófico/tratamento farmacológico , Pessoa de Meia-IdadeAssuntos
Lasers de Excimer/uso terapêutico , Terapia com Luz de Baixa Intensidade , Vitiligo/radioterapia , Adulto , Povo Asiático , Betametasona/análogos & derivados , Betametasona/uso terapêutico , Inibidores de Calcineurina/uso terapêutico , Terapia Combinada , Fármacos Dermatológicos/uso terapêutico , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Pigmentação da Pele , Tacrolimo/uso terapêutico , Vitiligo/tratamento farmacológicoRESUMO
To treat anal fissure, internal anal sphincterotomy may be associated with surgical risks and incidence of incontinence. Botulinum toxin injection into the anal sphincter is invasive and expensive. Headache and hypotension hindered topical treatment with glyceryl trinitrate. Greater patient compliance, potentiated efficacy, reduced side effects, and lower cost are the major advantages offered by the combination therapy. Therefore, combination topical gels of nifedipine (NIF), lidocaine hydrochloride (LDH) and betamethasone valerate (BMV) were prepared and evaluated regarding viscosity, pH, drug content, and in vitro release. Compatibility study of drug-drug and drug-excipient mixtures preceded the formulation. Stability study was performed. A prospective randomized clinical trial was conducted for six weeks to assess the efficacy of the optimized formula in the treatment of anal fissure either acute (AAF, 37 patients) or chronic (CAF, 34 patients) in comparison with three single drug market products. The compatibility was indicated except in case of LDH with each of poloxamer 407 (P407), methylparaben, and propylparaben as well as BMV with P407. The gels showed acceptable viscosity ranges, tolerated pH values, and drugs content limits complying with the pharmacopeial limit. The gel containing 10% Transcutol® (F2) was selected as optimized formula due to the significant (p < 0.05) enhancement in NIF release. The recommended storage temperature was 8 °C. In comparison with the market products, the optimized gel can be represented as a potential combination therapy of acute and chronic anal fissures as suggested by significantly increased healing% and significantly reduced pain, bleeding, anal discharge and itching without side effects.
Assuntos
Fissura Anal/tratamento farmacológico , Administração Tópica , Adulto , Idoso , Anestésicos Locais/administração & dosagem , Anestésicos Locais/uso terapêutico , Anti-Inflamatórios não Esteroides/administração & dosagem , Anti-Inflamatórios não Esteroides/uso terapêutico , Betametasona/administração & dosagem , Betametasona/uso terapêutico , Combinação de Medicamentos , Composição de Medicamentos , Quimioterapia Combinada , Excipientes , Feminino , Géis , Humanos , Lidocaína/administração & dosagem , Lidocaína/uso terapêutico , Masculino , Pessoa de Meia-Idade , Nifedipino/administração & dosagem , Nifedipino/uso terapêutico , Estudos Prospectivos , Vasodilatadores/administração & dosagem , Vasodilatadores/uso terapêutico , Adulto JovemRESUMO
To observe and analyze the clinical effect of cervical paravertebral nerve block combined with Mailuoning and Angelica sinensis injection in treatment of nerve-root type cervical spondylosis. 120 patients who have been accepted by our hospital for nerve-root type cervical spondylosis were selected as research objects. They were randomly divided into a research group and a control group, each containing 60 patients. The control group was applied with glucocorticoid nerve block therapy, while the research group was treated by cervical paravertebral nerve block combined with Mailuoning and Angelica sinensis injection. The total therapeutic response rates of two groups were compared. The total therapeutic response rate of the research group was relatively higher,P<0.05. Through comparing various clinical effect scores between two groups, the research group also had advantages over control group, P<0.05. The treatment satisfaction degree of the research group was also higher than that of control group, P<0.05. The application of cervical paravertebral nerve block combined with Mailuoning and Angelica sinensis injection can achieve better medical results and achieve higher treatment satisfaction degree.